Showing results (631-640 of 3,635) with videos related to

Sort By:
Pageof 364
Breast (Edinburgh, Scotland)|June 18, 2013
Fat grafting and stem cell enhanced fat grafting to the breast under oncological aspects--recommendations for patient selectionAnna Krumboeck, Pietro Giovanoli, Jan A Plock
Breast (Edinburgh, Scotland)|July 9, 2013
Prognostic factors of brain metastases from breast cancer: impact of targeted therapiesAntoine Laurent Braccini, David Azria, Simon Thezenas, et al.
Breast (Edinburgh, Scotland)|July 19, 2013
The impact of lobular and ductal breast cancer histology on the metastatic behavior and long term survival of breast cancer patientsT Korhonen, T Kuukasjärvi, H Huhtala, et al.
Breast (Edinburgh, Scotland)|April 10, 2013
The prognostic role of preoperative and (early) postoperatively change in CA15.3 serum levels in a single hospital cohort of primary operable breast cancersO Brouckaert, A Laenen, H Wildiers, et al.
Breast (Edinburgh, Scotland)|May 14, 2013
Trastuzumab therapy in Australia: which patients with HER2+ metastatic breast cancer are assessed for cardiac function?Christine Y Lu, Preeyaporn Srasuebkul, Anna K Drew, et al.
Breast (Edinburgh, Scotland)|May 14, 2013
'23 h Model' for breast surgery: an early experienceA J Hainsworth, C R Lobo, P Williams, et al.
Breast (Edinburgh, Scotland)|June 12, 2013
The course of Health Related Quality of Life in postmenopausal women with breast cancer from breast surgery and up to five years post-treatmentMaria Browall, Ulrika Östlund, Ingela Henoch, et al.
Breast (Edinburgh, Scotland)|April 13, 2012
Quantifying the number of lymph nodes identified in one-stage versus two-stage axillary dissection in breast cancerOlaf E Damgaard, Maj-Britt Jensen, Niels Kroman, et al.
Breast (Edinburgh, Scotland)|September 6, 2014
The Internet: What are our patients exposed to when considering breast reconstruction following mastectomy?Amy Light, Colin Munro, William Breakey, et al.
Breast (Edinburgh, Scotland)|September 25, 2013
Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: a sub-study from the NeoALTTO phase III trialHatem A Azim, Francoise Rothé, Claudia Monica Aura, et al.
Pageof 364